Digoxin overdose: Difference between revisions
m Protected "Digoxin overdose" [edit=sysop:move=sysop] |
No edit summary |
||
Line 17: | Line 17: | ||
---- | ---- | ||
<br> | <br> | ||
===Diagnosis=== | |||
====Electrocardiographic Findings==== | |||
* [[Bradyarrhythmias]]: | |||
:* AV block. Including [[complete AV block]] and [[Wenkebach]]. | |||
* [[Tachyarrhythmias]]: | |||
:* Junctional tachycardia | |||
:* Atrial tachycardia | |||
:* Ventricular ectopia, bigemini, monomorphic ventricular tachycardia, bidirectional ventricular tachycardia | |||
'''NB''' these effects are increased by hypokalemia. In extreme high concentrations rhythm disturbances (''ventricular tachycardia, ventricular fibrillation, atrial fibrillation'') may develop. | |||
===Discontinuation=== | ===Discontinuation=== | ||
Digoxin should be discontinued until all signs of toxicity are gone. Discontinuation may be all that is necessary if toxic manifestations are not severe and appear only near the expected time for maximum effect of the drug. ''[[Digoxin overdose#Overdosage topics|Return to top]]'' | Digoxin should be discontinued until all signs of toxicity are gone. Discontinuation may be all that is necessary if toxic manifestations are not severe and appear only near the expected time for maximum effect of the drug. ''[[Digoxin overdose#Overdosage topics|Return to top]]'' |
Revision as of 00:27, 24 September 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overdosage topics
Discontinuation
Potassium salts
Dialysis/exchange transfusion/cardiopulmonary bypass
Activated charcoal
Digoxin Immune Fab
Diagnosis
Electrocardiographic Findings
- AV block. Including complete AV block and Wenkebach.
- Junctional tachycardia
- Atrial tachycardia
- Ventricular ectopia, bigemini, monomorphic ventricular tachycardia, bidirectional ventricular tachycardia
NB these effects are increased by hypokalemia. In extreme high concentrations rhythm disturbances (ventricular tachycardia, ventricular fibrillation, atrial fibrillation) may develop.
Discontinuation
Digoxin should be discontinued until all signs of toxicity are gone. Discontinuation may be all that is necessary if toxic manifestations are not severe and appear only near the expected time for maximum effect of the drug. Return to top
Potassium salts
There has been one reported case of massive overdosage with Nifedipine extended-release tablets. The main effects of ingestion of approximately 4800 mg of Nifedipine extended-release in a young man attempting suicide as a result of cocaine-induced depression was initial dizziness, palpitations, flushing, and nervousness. Within several hours of ingestion, nausea, vomiting, and generalized edema developed. No significant hypotension was apparent at presentation, 18 hours post-ingestion. Electrolyte abnormalities consisted of a mild, transient elevation of serum creatinine, and modest elevations of LDH and CPK, but normal SGOT. Vital signs remained stable, no electrocardiographic abnormalities were noted and renal function returned to normal within 24 to 48 hours with routine supportive measures alone. No prolonged sequelae were observed.Potassium salts may be used, particularly if hypokalemia is present. Potassium chloride in divided oral doses totaling 1 to 1.5 mEq K+ per kilogram (kg) body weight may be given provided renal function is adequate (1 gram of potassium chloride contains 13.4 mEq K+). When correction of the arrhythmia with potassium is urgent and the serum potassium concentration is low or normal, approximately 0.5 mEq/kg of potassium per hour may be given intravenously in 5% dextrose injection. The intravenous solution of potassium should be dilute enough to avoid local irritation; however, especially in infants care must be taken to avoid intravenous fluid overload. ECG monitoring should be performed to watch for any evidence of potassium toxicity (e.g., peaking of T waves) and to observe the effect on the arrhythmia. The infusion may be stopped when the desired effect is achieved.
Note: Potassium should not be used and may be dangerous in heart block due to Digoxin, unless primarily related to supraventricular tachycardia. Return to top
Dialysis/exchange transfusion/cardiopulmonary bypass
Because of its large extravascular volume of distribution, Digoxin is not effectively removed from the body by dialysis, by exchange transfusion, or during cardiopulmonary bypass. Return to top
Activated charcoal
Multiple doses of activated charcoal have been found effective in at least 1 case report, and may be of use while the need for and availability of Digoxin specific antibody fragments are being assessed. In advanced heart block, temporary ventricular pacing may be beneficial. Return to top
Digoxin Immune Fab
Digoxin Immune Fab (Ovine) [DIGIBIND®, DIGIFAB®] may be indicated for the treatment of patients with life-threatening or potentially life-threatening Digoxin toxicity or overdose. Return to top
Adapted from the FDA Package Insert.